Prismasol Injection
FDA Label NDC 24571-108

23 label sections · Submitted to the FDA by Vantive Us Healthcare Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Vantive Us Healthcare Llc for the product Prismasol (NDC 24571-108). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 administration instructions, 2.2 dosing considerations, 2.3 preparing the solution, other, 2.4 adding drugs to the solutions, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

1 Indications And Usage

PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

2.1 Administration Instructions

Visually inspect PRISMASOL and PHOXILLUM for particulate matter and discoloration prior to administration.

Administration should only be under the direction of a physician competent in intensive care treatment including CRRT. Use only with extracorporeal dialysis equipment appropriate for CRRT.

The prepared solution is for single patient use only.

Aseptic technique should be used throughout administration to the patient.

Discard any unused solution.

2.2 Dosing Considerations

PRISMASOL replacement solutions contain 4 different combinations of active ingredients (7 different products with varying ingredient amounts). PHOXILLUM replacement solutions contain 2 different combinations of active ingredients (2 different products with varying ingredient amounts). PRISMASOL and PHOXILLUM are supplied in a two-compartment bag that must be mixed immediately prior to use [see Dosage and Administration (2.3)]:

  • Small compartment A (250 mL) containing an electrolyte solution, and
  • Large compartment B (4750 mL) containing the buffer solution.
  • See Table 1 for the concentrations of the active ingredients (after mixing) in these 9 different replacement solutions (total volume is 5 Liters).

    Table 1: Concentrations of Active Ingredients in the 7 PRISMASOL and 2 PHOXILLUM Replacement Solutions after Mixing
    Ca2+
    mEq/L
    HCO3-
    mEq/L
    K+
    mEq/L
    Mg2+
    mEq/L
    Na+
    mEq/L
    HPO42-
    mmol/L
    Cl-
    mEq/L
    Lactate
    mEq/L
    Dextrose
    mg/dL
    Osmolarity
    mOsm/L
    Ca2+ = calcium, HCO3- = bicarbonate, K+ = potassium, Mg2+ = magnesium, Na+ = sodium, HPO42- = phosphate, Cl- = chloride; osmolarity is estimated

    PRISMASOL Replacement Solutions

    BGK0/2.5

    2.5

    32

    0

    1.5

    140

    0

    109

    3

    100

    292

    BGK4/2.5

    2.5

    32

    4

    1.5

    140

    0

    113

    3

    100

    300

    BGK2/3.5

    3.5

    32

    2

    1

    140

    0

    111.5

    3

    100

    296

    BGK2/0

    0

    32

    2

    1

    140

    0

    108

    3

    100

    291

    B22GK4/0

    0

    22

    4

    1.5

    140

    0

    120.5

    3

    100

    296

    BGK4/0/1.2

    0

    32

    4

    1.2

    140

    0

    110.2

    3

    100

    295

    BK0/0/1.2

    0

    32

    0

    1.2

    140

    0

    106.2

    3

    0

    282

    PHOXILLUM Replacement Solutions

    BK4/2.5

    2.5

    32

    4

    1.5

    140

    1

    114.5

    0

    0

    294

    B22K4/0

    0

    22

    4

    1.5

    140

    1

    122

    0

    0

    290

    The mode of therapy, solute formulation, flow rates, and length of PRISMASOL and PHOXILLUM replacement therapy in CRRT should be established by a physician based on the patient’s clinical condition, blood concentration of phosphate and other electrolytes, acid-base and glucose balance. Administer either PRISMASOL or PHOXILLUM into the extracorporeal circuit:

    • Before (pre-dilution) the hemofilter or hemodiafilter,
    • After (post-dilution) the hemofilter or hemodiafilter, or
    • Before and after the hemofilter or hemodiafilter.

2.3 Preparing The Solution

Use only if the overwrap is not damaged, all seals are intact, peel seal is not broken, and the solution is clear.

The solution may be warmed to 37°C/98.6°F prior to removing the overwrap to enhance patient comfort. However, only dry heat should be used. Solutions should not be heated in water or in a microwave oven. After heating, verify that the solution remains clear and contains no particulate matter.

The solutions are supplied in two different two-compartment bags made of polyolefin with a peel seal separating compartment A and B (see Figure 1).

Follow the instructions below when connecting the solution bags for correct use of the access ports.

Other

Instructions for preparing solutions supplied in a two-compartment, polyolefin bag with a peel seal:

Figure 1 (Image 01)

Figure 1 (Image 01)

Figure 1

Figure 2

Figure 2 (Image 02)

Figure 2 (Image 02)

Step 1 Immediately before use, remove the overwrap from the bag and mix the solutions in the two different compartments. After removing the overwrap, inspect the bag for leakage by pressing firmly on the bag. Discard the bag if any leakage is detected since sterility cannot be assured. As soon as the overwrap is removed, the reconstitution of compartments A and B should be done and the mixed solution should be used immediately.

After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment.

Hold the small compartment with both hands and squeeze it until an opening is created in the peel seal. (See Figure 2 beside)

Figure 3

Figure 3 (Image 03)

Figure 3 (Image 03)

Step 2 Squeeze with both hands on the large compartment until the peel seal between the two compartments is entirely open. Shake gently to mix. (See Figure 3 beside)

The solution is now ready to use and the bag can be hung on the equipment.

Figure 4a

Figure 4a (Image 04)

Figure 4a (Image 04)

Step 3 The replacement line may be connected to the bag through either of the luer connector or the injection connector (spike connector).

Step 3a The luer connector is a needle-less and swabbable connector. Remove the cap with a twist and pull motion, and connect the male luer lock on the replacement line to the female luer receptor on the bag. (See Figure 4a beside)

Ensure that the connection is fully seated and tighten. The connector is now open. Verify that the fluid is flowing freely during use.

When the replacement line is disconnected from the luer connector, the connector will close and the flow of the solution will stop.

Figure 4b

Figure 4b (Image 05)

Figure 4b (Image 05)

Step 3b If the injection connector (spike connector) is used, first remove the snap-off cap. Then introduce the replacement line spike through the swabbable rubber septum of the bag connector. (See Figure 4b beside)

Ensure that the spike is fully inserted and verify that the fluid is flowing freely during use.

PHOXILLUM Solutions:

Phosphate: Phosphate up to 0.2 mmol/L may be added to the solution. Use sodium phosphate if adding phosphate to bag. The total phosphate concentration should not exceed 1.2 mmol/L.

2.4 Adding Drugs To The Solutions

After mixing, additional drugs may be added to the bag via injection connector (spike connector) in large compartment B. In general, administer drugs other than phosphate through a different access line.

When introducing drugs, use aseptic techniques and mix thoroughly prior to connecting the solution bag to the extracorporeal circuit.

Do not use if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals after addition of medication.

Phosphate: Up to 1.2 mmol/L of phosphate can be added to the bag as potassium phosphate or sodium phosphate. The total potassium concentration of PRISMASOL solution should not exceed 4 mEq/L. Use sodium phosphate to add phosphate if the total potassium concentration in PRISMASOL solution is 4 mEq/L.

4 Contraindications

PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.

5.1 Electrolyte And Volume Abnormalities

PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately [see Dosage and Administration (2)].

PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

5.2 Blood Glucose Abnormalities

The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

6 Adverse Reactions

The following adverse reactions have been identified during postapproval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Metabolic acidosis
  • Hypotension
  • Acid-base disorders
  • Electrolyte imbalance including calcium ionized increased (reported in PRISMASOL solutions containing calcium), hyperphosphatemia, and hypophosphatemia
  • Fluid imbalance

7 Drug Interactions

As with the use of other replacement solutions, blood concentrations of dialyzable drugs may be reduced by CRRT due to their removal by the hemofilter or hemodiafilter. The blood concentrations of certain drugs may need to be monitored and appropriate therapy implemented to correct for removal during treatment.

7.1 Citrate

When used as an anticoagulant, citrate contributes to the overall buffer load and can reduce plasma calcium levels. Select the PRISMASOL/PHOXILLUM formulation(s) accordingly.

Risk Summary

PRISMASOL and PHOXILLUM are pharmacologically inactive solutions. While there are no adequate and well controlled studies in pregnant women, appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with PRISMASOL and PHOXILLUM solutions.

The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

The components of PRISMASOL and PHOXILLUM solutions are excreted in human milk. Appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant.

Clinical Considerations

Maintenance of normal acid-base balance is important for fetal well-being.

8.4 Pediatric Use

Safety and effectiveness have been established based on published clinical data of CRRT replacement solutions with compositions similar to PRISMASOL and PHOXILLUM used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old.

8.5 Geriatric Use

The experience with PRISMASOL and PHOXILLUM solutions in geriatric patients has not identified novel concerns.

11 Description

PRISMASOL and PHOXILLUM solutions are clear, sterile, free of bacterial endotoxins and contain no bacteriostatic or antimicrobial agents. These solutions are used in Continuous Renal Replacement Therapies (CRRT) as a replacement solution in hemofiltration and hemodiafiltration. Depending on the product (see Table 2), the two compartments contain:

Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl2 • 2H2O).

Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl2 • 6H2O).

Sodium chloride, USP, is chemically designated NaCl.

Potassium chloride, USP, is chemically designated KCl.

Sodium bicarbonate, USP, is chemically designated NaHCO3.

Dextrose, USP, is chemically designated D-Glucose anhydrous (C6H12O6) or D-Glucose monohydrate (C6H12O6 • H2O).

Lactic acid, USP, is chemically designated CH3CH(OH)COOH.

Dibasic sodium phosphate, USP, is chemically designated as disodium hydrogen phosphate, dihydrate (Na2HPO4 • 2H2O)

Table 2 - Compartment Composition (Before Mixing)
Compartment A (g/L)Compartment B (g/L)
Calcium Chloride ∙ 2H2OMagnesium Chloride ∙ 6H2ODextrose anhydrous (as monohydrate)Lactic AcidSodium ChlorideSodium bicarbonatePotassium ChlorideSodium Phosphate ∙ 2H2O

PRISMASOL SOLUTIONS

BGK 0/2.5

3.68

3.05

20 (22)

5.40

6.46

3.09

0

0

BGK 4/2.5

3.68

3.05

20 (22)

5.40

6.46

3.09

0.314

0

BGK 2/3.5

5.15

2.03

20 (22)

5.40

6.46

3.09

0.157

0

BGK 2/0

0

2.03

20 (22)

5.40

6.46

3.09

0.157

0

B22GK 4/0

0

3.05

20 (22)

5.40

7.07

2.21

0.314

0

BK 0/0/1.2

0

2.44

0 (0)

5.40

6.46

3.09

0

0

BGK 4/0/1.2

0

2.44

20 (22)

5.40

6.46

3.09

0.314

0

PHOXILLUM SOLUTIONS

BK 4/2.5

3.68

3.05

0 (0)

0

6.34

3.09

0.314

0.187

B22K 4/0

0

3.05

0 (0)

0

6.95

2.21

0.314

0.187

The pH of the final solution is in the range of 7.0 to 8.5.

12.1 Mechanism Of Action

PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations.

PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration. Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.

12.3 Pharmacokinetics

The distribution of electrolytes, bicarbonate, and dextrose is determined by the patient's clinical condition, metabolic status, and residual renal function.

The elimination and replacement of water, electrolytes and buffer depend on the patient's electrolyte and acid-base balance, metabolic status, residual renal function and ongoing physiologic losses through intestinal, respiratory and cutaneous routes.

16 How Supplied/Storage And Handling

PRISMASOL and PHOXILLUM solutions are supplied in a two-compartment bag made of polyolefin. The 5000 mL bag is composed of a small compartment (250 mL) and a large compartment (4750 mL). The two compartments are separated by a peel seal.

The bag is overwrapped with a transparent overwrap. See Table 2 for the concentrations of the active ingredients in each compartment for each product [see Description (11)].

Container

Fill Volume

NDC

PRISMASOL Solutions

PRISMASOL BGK0/2.5

5000 mL

24571-108-06

PRISMASOL BGK4/2.5

5000 mL

24571-105-06

PRISMASOL BGK2/3.5

5000 mL

24571-103-06

PRISMASOL BGK2/0

5000 mL

24571-102-06

PRISMASOL B22GK4/0

5000 mL

24571-111-06

PRISMASOL BK0/0/1.2

5000 mL

24571-113-06

PRISMASOL BGK4/0/1.2

5000 mL

24571-114-06

PHOXILLUM Solutions

PHOXILLUM BK4/2.5

5000 mL

24571-116-06

PHOXILLUM B22K4/0

5000 mL

24571-117-06

Not all formulations may be marketed.

Storage And Handling

Storage conditions

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]

Do not freeze or expose to excessive heat. Do not use if precipitate has formed or if container seals have been damaged.

Manufactured for:
Vantive US Healthcare LLC
Deerfield, Illinois 60015

07-19-00-9693

Vantive, Phoxillum and PrismaSol are trademarks of Vantive Health LLC, or its affiliates

Package/Label Display Panel

Prismasol Representative Container Label Bgk0/2.5 (Image 06.jpg)

Prismasol Representative Container Label Bgk0/2.5 (Image 06.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-108-06

OK+
mEq/L

2.5 Ca2+
mEq/L

PrismaSol BGK0/2.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Calcium chloride • 2H2O

3.68

Magnesium chloride • 6H2O

3.05

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

6.46

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 292 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

1.25

0.75

140

109.0

3.0

32

0

5.5

mEq/L

2.5

1.5

140

109.0

3.0

32

0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091613
Product # 110240

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5278

Prismasol Representative Container Label Bgk4/2.5 (Image 07.jpg)

Prismasol Representative Container Label Bgk4/2.5 (Image 07.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-105-06

4K+
mEq/L

2.5 Ca2+
mEq/L

PrismaSol BGK4/2.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Calcium chloride • 2H2O

3.68

Magnesium chloride • 6H2O

3.05

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

6.46

Potassium chloride

0.314

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 300 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

1.25

0.75

140

113.0

3.0

32

4.0

5.5

mEq/L

2.5

1.5

140

113.0

3.0

32

4.0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091637
Product # 110242

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy
07-25-00-5280

Prismasol Representative Container Label Bgk2/3.5 (Image 08.jpg)

Prismasol Representative Container Label Bgk2/3.5 (Image 08.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-103-06

2K+
mEq/L

3.5 Ca2+
mEq/L

PrismaSol BGK2/3.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Calcium chloride • 2H2O

5.15

Magnesium chloride • 6H2O

2.03

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

6.46

Potassium chloride

0.157

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment

Rx only
A
250 mL

B
4750 mL

Theoretical osmolarity: 296 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

1.75

0.5

140

111.5

3.0

32

2.0

5.5

mEq/L

3.5

1.0

140

111.5

3.0

32

2.0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091644
Product # 110243

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy
07-25-00-5281

Prismasol Representative Container Label Bgk2/0 (Image 09.jpg)

Prismasol Representative Container Label Bgk2/0 (Image 09.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-102-06

2K+
mEq/L

0Ca2+
mEq/L

PrismaSol BGK2/0
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Magnesium chloride • 6H2O

2.03

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

6.46

Potassium chloride

0.157

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 291 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

0

0.5

140

108.0

3.0

32

2.0

5.5

mEq/L

0

1.0

140

108.0

3.0

32

2.0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091651
Product # 110244

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5282

Prismasol Representative Container Label B22gk4/0 (Image 10.jpg)

Prismasol Representative Container Label B22gk4/0 (Image 10.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-111-06

4K+
mEq/L

Bicarbonate 22

0Ca2+
mEq/L

PrismaSol B22GK4/0
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Magnesium chloride • 6H2O

3.05

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

7.07

Potassium chloride

0.314

Lactic acid

5.40

Sodium bicarbonate

2.21

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 296 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

0

0.75

140

120.5

3.0

22

4.0

5.5

mEq/L

0

1.5

140

120.5

3.0

22

4.0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414116781
Product # 115001

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5285

Prismasol Representative Container Label Bk0/0/1.2 (Image 11.jpg)

Prismasol Representative Container Label Bk0/0/1.2 (Image 11.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-113-06

0K+
mEq/L

0Ca2+
mEq/L

PrismaSol BK0/0/1.2
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Magnesium chloride • 6H2O

2.44

Sodium chloride

6.46

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 282 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

0

0.6

140

106.2

3.0

32

0

0

mEq/L

0

1.2

140

106.2

3.0

32

0

(0 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091309
Product # 110239

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5277

Prismasol Representative Container Label Bgk4/0/1.2 (Image 12.jpg)

Prismasol Representative Container Label Bgk4/0/1.2 (Image 12.jpg)

Container Label

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-114-06

4K+
mEq/L

0Ca2+
mEq/L

PrismaSol BGK4/0/1.2
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)

A

B

Magnesium chloride • 6H2O

2.44

Dextrose anhydrous

20.0

(as dextrose monohydrate)

22.0

Sodium chloride

6.46

Potassium chloride

0.314

Lactic acid

5.40

Sodium bicarbonate

3.09

Water for injections q.s, Carbon dioxide for pH adjustment


A
250 mL

B
4750 mL

Theoretical osmolarity: 295 mOsm/L pH: 7.0 – 8.5

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Lactate
C3H5O3-

Bicarbonate
HCO3-

Potassium
K+

Dextrose

mmol/L

0

0.6

140

110.2

3.0

32

4.0

5.5

mEq/L

0

1.2

140

110.2

3.0

32

4.0

(100 mg/dL)

 

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091620
Product # 110241

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5279

Phoxillum Representative Container Label Bk4/2.5 (Image 13)

Phoxillum Representative Container Label Bk4/2.5 (Image 13)

Container Label

Mixing steps
① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Compartment B

Barcode
NDC# 24571-116-06

4K+
mEq/L

1 Phosphate
mmol/L

2.5 Ca2+
mEq/L

Phoxillum BK4/2.5
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution, each 1000 mL contains (g):

A

B

Calcium chloride • 2H2O

3.68

Magnesium chloride • 6H2O

3.05

Sodium chloride

6.34

Potassium chloride

0.314

Sodium bicarbonate

3.09

Dibasic sodium phosphate • 2H2O

0.187

Water for injections q.s

Rx only
A
250 mL

B
4750 mL

After reconstitution, A + B

Calcium
Ca2+

Magnesium
Mg2+

Sodium
Na+

Chloride
Cl-

Bicarbonate
HCO3-

Potassium
K+

Phosphate
HPO42-

Dextrose

mmol/L

1.25

0.75

140

114.5

32

4.0

1

0

mEq/L

2.5

1.5

140

114.5

32

4.0

(1 mmol/L)

(0 mg/dL)

  •  Theoretical osmolarity: 294 mOsm/L pH: 7.0 – 8.5
  • Mix both compartments before use.
    See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
    Confirm the integrity of the packaging. Use only if solution is clear. For single use only. DISCARD ANY UN-
    USED SOLUTION. Store at +20°C to +25°C (+68°F to +77°F); excursions permitted to +15°C - +30°C (+59°F
    to +86°F). [See USP Controlled Room Temperature]. Do not freeze or expose to excessive heat. As soon as the
    overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted
    solution should be used immediately. After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for
    further information). This product is not made with natural rubber latex. Carbon dioxide and hydrochloric
    acid or diluted hydrochloric acid added for pH adjustment.

    5000 mL
    EAN-14: 07332414116040
    Product # 114905

    VANTIVE Logo

    Batch No. and expiry date are printed on the back of the bag.
    Manufactured for:
    Vantive US Healthcare LLC
    Deerfield IL 60015 USA
    Made in Italy

    REPLACEMENT
    Solution for Continuous Renal Replacement Therapy

    07-25-00-6254

    Phoxillum Representative Container Label B22k4/0 (Image 14)

    Phoxillum Representative Container Label B22k4/0 (Image 14)

    Container Label

    Mixing steps

    ① SQUEEZE TOP corners to break seal

    ② Squeeze BAG SIDES to fully open seal

    Compartment B

    Barcode
    NDC# 24571-117-06

    4K+
    mEq/L

    0 Ca2+
    mEq/L

    22 Bicarbonate
    mEq/L

    1 Phosphate
    mmol/L

    Phoxillum B22K4/0
    Replacement Solution for Continuous Renal Replacement Therapy

    Before reconstitution, each 1000 mL contains (g):

    A

    B

    Magnesium chloride • 6H2O

    3.05

    Sodium chloride

    6.95

    Potassium chloride

    0.314

    Sodium bicarbonate

    2.21

    Dibasic sodium phosphate • 2H2O

    0.187

    Water for injections q.s

    Rx only
    A
    250 mL

    B
    4750 mL

    After reconstitution, A + B

    Calcium
    Ca2+

    Magnesium
    Mg2+

    Sodium
    Na+

    Chloride
    Cl-

    Bicarbonate
    HCO3-

    Potassium
    K+

    Phosphate
    HPO42-

    Dextrose

    mmol/L

    0

    0.75

    140

    122.0

    22

    4.0

    1

    0

    mEq/L

    0

    1.5

    140

    122.0

    22

    4.0

    (1 mmol/L)

    (0 mg/dL)

    •  Theoretical osmolarity: 290 mOsm/L pH: 7.0 – 8.5
    • Mix both compartments before use.

      See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
      Confirm the integrity of the packaging. Use only if solution is clear. For single use only. DISCARD ANY UN-
      USED SOLUTION. Store at +20°C to +25°C (+68°F to +77°F); excursions permitted to +15°C to +30°C (+59°F
      to +86°F). [See USP Controlled Room Temperature]. Do not freeze or expose to excessive heat. As soon as the
      overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted solution
      should be used immediately. After removal of the overwrap, the solution is stable for 24 hours including the duration
      of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for
      further information). This product is not made with natural rubber latex. Carbon dioxide and hydrochloric or diluted hydrochloric acid added for pH adjustment.

      5000 mL
      EAN-14: 07332414116057
      Product # 114906

      VANTIVE Logo

      Batch No. and expiry date are printed on the back of the bag.
      Manufactured for:
      Vantive US Healthcare LLC
      Deerfield IL 60015 USA
      Made in Italy

      REPLACEMENT
      Solution for Continuous Renal Replacement Therapy

      07-25-00-6255

* Please review the disclaimer below.